Without limiting the provisions of Section. 3.7.1, the Parties acknowledge and agree that, other than as set out in Sections 5.4 and 12.3, Salix has no obligation to Develop or Commercialize any Licensed Product or any obligation to satisfy the conditions to the milestone payments set forth in Section 6.2 or to achieve any particular level of additional consideration or other payments (or additional consideration or other payments payable to Redhill under Section 6.3).β 5.3. Article 5 is hereby amended by the addition of the following after Section 5.3:
Appears in 2 contracts
Sources: Agreement (RedHill Biopharma Ltd.), Amendment No. 1 to Agreement (RedHill Biopharma Ltd.)